Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade
Breast Cancer Research and Treatment · 2024-06 · 205 (3) · 579-587
DOI: 10.1007/s10549-024-07290-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 07.03.2024. Verfasst von Jorge Avila und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA. jorgeavilamd@gmail.com. Hauptthemen laut MEDLINE: Brain Neoplasms, Breast Neoplasms, SEER Program. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Susan G. Komen.
Abstract (Originalsprache)
PURPOSE: There have been significant advances in the treatment of metastatic breast cancer (BC) over the past years, and long-term outcomes after a diagnosis of brain metastases are lacking. We aimed to identify predictors of brain metastases at initial breast cancer diagnosis, describe overall survival (OS) in the past decade, and identify factors associated with OS after brain metastases diagnosis. METHODS: We evaluated patients with de novo stage IV BC using the Surveillance, Epidemiology and End Results database from 2010 to 2019. Multivariate logistic regression was conducted to assess predictors of brain metastases at initial breast cancer diagnosis. OS was estimated using the Kaplan-Meier method and log rank test was used to compare differences between groups. Cox regression was used to assess associations between several variables and OS. RESULTS: 1,939 patients with brain metastases at initial breast cancer diagnosis were included. Factors associated with this presentation were grade III/IV tumors, ductal histology, hormone receptor (HR)-negative/human epidermal growth factor receptor 2 (HER2)-positive subtype, and extracranial metastases. Patients with HR-positive/HER2-positive disease had the longest OS (median 18 months) and 12.2% were alive at 8 years. Factors associated with shorter OS included older age, lower income, triple-negative subtype, higher grade, and visceral metastases. CONCLUSION: Over the last decade, the median OS of patients with brain metastases at initial breast cancer diagnosis remained poor; however, a substantial minority survive 5 or more years, with rates higher in patients with HER2-positive tumors. In addition to tumor subtype, OS varied according to age, extracranial metastases, and sociodemographic factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA. jorgeavilamd@gmail.com.
- Grupo Oncológico Cooperativo Del Sur (GOCS), Neuquén, Argentina.
- Medical Oncology, Susan F. Smith Center for Women's Cancer, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Förderung
- Susan G. Komen
Zitieren
APA
Avila, J., Leone, J., Vallejo, C. T., Lin, N. U., & Leone, J. P. (2024). Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade. Breast Cancer Research and Treatment, 205(3), 579-587. https://doi.org/10.1007/s10549-024-07290-1
Vancouver
Avila J, Leone J, Vallejo CT, Lin NU, Leone JP. Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade. Breast Cancer Research and Treatment. 2024;205(3):579-587. doi:10.1007/s10549-024-07290-1
BibTeX
@article{Avila2024,
author = {Avila, Jorge and Leone, Julieta and Vallejo, Carlos T and Lin, Nancy U and Leone, José P},
title = {Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {205},
number = {3},
pages = {579--587},
doi = {10.1007/s10549-024-07290-1}
}
EUVIMED